Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

July 30, 2020

Study Completion Date

July 30, 2020

Conditions
Healthy
Interventions
DRUG

Cesol (Test)

Participant will receive coated cesol tablet in sequence 1 (Day 1 and Day 15) and in sequence 2 (Day 8 and Day 22). A washout period of 7 days will be maintained between 4 treatment periods.

DRUG

Biltricide (Reference)

Participant will receive biltricide tablet in Sequence 1 (Day 8 and Day 22) and in sequence 2 (Day 1 and Day 15). A washout period of 7 days will be maintained between 4 treatment periods.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04314037 - Bioequivalence Study of Coated Cesol Tablet Formulation Versus Biltricide | Biotech Hunter | Biotech Hunter